Thiazolidinediones and PPAR-γsystem in the hepatic damnage's repair;Tiazolidindieni e sistema PPAR-γ nella riparazione del danno epatico

Recenti Progressi in Medicina

Volumn 93, Issue 1, 2002, Pages 9-15

  Marra, Fabio ^a   Pastacaldi, Sabrina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Diabetes; Hepatic damnage; Hepatic stellate cells; Inflammation; Liver fibrosis; Nuclear hormone receptors; Obesity; PPARs; Thiazolidinediones; Troglitazone

Indexed keywords

ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; FATTY ACID; ICOSANOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; CANCER; HUMAN; INFLAMMATION; LIVER FIBROSIS; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; STELLATE CELL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CHROMANS; DIABETES MELLITUS, TYPE 2; EICOSANOIDS; FATTY ACIDS; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIVER CIRRHOSIS; NEOPLASMS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RESEARCH; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0036155649     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
2. Peroxisome proliferator-activated receptors
3. Regulation of lipid and lipoprotein metabolism by PPAR activators
4. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
5. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
6. Mechanism of action of fibrates on lipid and lipoprotein metabolism
7. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting
8. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
9. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
10. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
11. The SRC family of nuclear receptor coactivators
12. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
13. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
14. Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo
15. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
16. Lessons from the glitazones: A story of drug development
17. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
18. Thiazolidinediones: An update
19. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
20. PPAR gamma is required for placental, cardiac, and adipose tissue development
21. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
22. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
23. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
24. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues
25. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents
26. The hormone resistin links obesity to diabetes
27. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
28. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
29. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
30. Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: Ending the heartache
31. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
32. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
33. Loss-of-function mutations in PPAR gamma associated with human colon cancer
34. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
35. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
36. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma
37. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
38. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
39. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
40. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase
41. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies
42. Hepatic stellate cells and the regulation of liver inflammation
43. Peroxisome proliferator-activated receptor γ transcriptional activation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells
44. Ligands of peroxisome-proliferator activated receptor-γ modulate profibrogenic and pro-inflammatory actions in hepatic stellate cells
45. Peroxisome proliferator-activated receptors and hepatic stellate cells activation
46. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines
47. 15-Deoxy-12,14 -prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors
48. PPARγ and the treatment of insulin resistance